Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $600 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a $600 price target.
July 23, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a $600 price target.
The reiteration of an Overweight rating and a high price target of $600 by a reputable analyst is likely to positively impact Elevance Health's stock price in the short term. This indicates strong confidence in the company's performance and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100